20241101-华安证券-新华医疗-600587.SH-三季度符合预期_看好设备更新落地获益_4页_448kb

新华医疗三季报分析报告总结

中文总结：
新华医疗发布2024年三季报业绩：前三季度营收742.3亿元（同比+145%），归母净利润61.7亿元（同比+663%），扣非净利润60.7亿元（同比+936%）。三季度单季营收223.7亿元（同比-3.2%），净利润13.3亿元（同比+1065%）。公司坚持“调结构、强主业、提效益、防风险”方针，聚焦医疗器械和制药装备主业，获多项高端设备注册证。毛利率和净利率保持稳定，预计2024-2026年营收和净利润年均增长超50%，维持“买入”评级。核心风险包括政策波动、设备更新不及预期及行业竞争加剧。

English Summary:
Xinhua Medical reported strong Q3 performance with RMB 74.23 billion in revenue (+145% YoY) and RMB 6.17 billion in net profit attributable to shareholders (+663% YoY). Focused on medical devices and pharmaceutical equipment, the company secured multiple high-value certifications and maintained gross/net margins. Analysts maintain a "Buy" rating, projecting 14-15X PE by 2026, with fiscal risks including policy shifts, device update delays, and market competition.